Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)
A Phase III, Randomized, Double-blind, Active Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine Administered as a Series of 2 Infant Doses and 1 Toddler Dose in Healthy Infants
A Phase III clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in infants aged approximately 2 months (42 to 89 days).
The objective of the study is to evaluate the immunogenicity and safety of Sinovac PCV13. The trial is a randomized, double-blind, active controlled phase III clinical trial.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
A phase III clinical trial of the study of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) developed by Sinovac Life Science Co., Ltd (Sinovac) will be conducted in Philippines infants aged approximately 2 months (42 to 89 days).
The trial is a randomized, double-blind, active controlled study. The objective of this study is to evaluate the immunogenicity and safety of PCV13 manufactured by Sinovac Life Science Co., Ltd. The active control vaccine is Prevenar 13™ manufactured by Pfizer.
About 500 infants aged approximately 2 months (42 to 89 days) will be enrolled. Participants will be randomized in 1:1 ratio to the test group and control group.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Edison Alberto
- Numero di telefono: (046)471-0996/+639171490841
- Email: edisonalberto@rocketmail.com
Luoghi di studio
-
-
Cavite
-
Imus, Cavite, Filippine
- Health Index Multispecialty Clinic (HIMC) Research and Development on Medical Sciences
-
Contatto:
- Edison R. Alberto
- Numero di telefono: (046)471-0996/+639171490841
- Email: edisonalberto@rocketmail.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
- Bambino
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Health infants aged approximately 2 months (42 to 89 days)
- Have a parent/legal guardian who has provided written informed consent after being fully informed about the study.
- Be able to provide the vaccination records since birth.
- The infant's mother is tested negative for HIV, syphilis, hepatitis B, and hepatitis C before the infant's enrollment to this study (test results obtained during pregnancy are acceptable, if provided).
Exclusion Criteria:
- Previous vaccination of any licensed or investigational pneumococcal vaccine, or planned receipt during the study participation;
- Previous vaccination of vaccines containing the component of diphtheria, tetanus, pertussis, poliomyelitis, and/or Hib vaccine.
- Previous receipt of ≥2 doses of hepatitis B vaccine; or receipt of a single hepatitis B vaccine dose administered at >30 days old.
- History of severe adverse reaction to previous vaccinations and/or serious allergic reactions (eg, anaphylaxis) to any vaccine component.
- History of any laboratory confirmed pneumococcal bacterial pneumonia or invasive pneumococcal diseases caused by S pneumoniae.
- Premature infants (born before week 37 of gestation).
- Severe congenital malformations, developmental disorders, clinically significant genetic defects, malnutrition.
- Autoimmune diseases or immunodeficiency/immunosuppression.
- Serious chronic diseases such as Down's syndrome, diabetes, sickle cell anemia, or neurological disorders.
- Abnormal coagulation functions (e.g., coagulation factor deficiency, blood coagulation diseases, platelet disorders).
- Received immunosuppressive for ≥14 days (e.g., prednisone equivalent of ≥2 mg/kg), or cytotoxic drug before enrollment, or plans to receive these treatments during the study participation.
- Received blood products before investigational vaccine inoculation, or plan to receive these treatments during study participation.
- Received other investigational drugs/vaccines before enrollment, or plan to receive investigational drugs/vaccines during study participation.
- Received live attenuated vaccines or nucleic-acid vaccines within 14 days before enrollment.
- Received subunit or inactivated vaccines within 7 days before enrollment.
- Acute diseases or acute exacerbations of chronic diseases within 7 days before enrollment.
- Axillary temperature ≥ 37.5°C before enrollment.
- Any other factors judged by the investigators as unsuitable for participation.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Sinovac PCV 13
250 participants aged 2 months (42 to 89 days) will receive 3 doses of Sinovac PCV13 at approximately 2, 4 and 12-15 months of age.Route of administration is intramuscular injection at anterolateral thigh for infants aged younger than 12 months, and at deltoid muscle of upper arm for children aged older than 12 months.
|
One dose of Sinovac PCV13 (0.5ml) was administered at 2, 4, and 12-15 months of age.
|
|
Comparatore attivo: Prevenar 13™
250 participants aged 2 months (42 to 89 days) will receive 3 doses of Prevenar 13™ at approximately 2, 4 and 12-15 months of age.Route of administration is intramuscular injection at anterolateral thigh for infants aged younger than 12 months, and at deltoid muscle of upper arm for children aged older than 12 months.
|
One dose of Prevenar 13™ (0.5ml) was administered at 2, 4, and 12-15 months of age.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of participants with pneumococcal serotype-specific IgG antibody concentrations≥0.35 μg/mL .
Lasso di tempo: 30 days after dose 2.
|
Non-inferiority criterion: The lower limit of the two-sided 95% CI for the difference (Sinovac-PCV13 minus Prevenar 13™) > -10% for each serotype at 30 days after dose 2.
|
30 days after dose 2.
|
|
Geometric mean concentrations (GMCs) of serotype-specific IgG antibody.
Lasso di tempo: 30 days after dose 2
|
Non-inferiority criterion: The lower limit of the two-sided 95% CI for the GMC ratio (Sinovac-PCV13/Prevenar 13™) > 0.5 for each serotype at 30 days after dose 2.
|
30 days after dose 2
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incidenza delle reazioni avverse
Lasso di tempo: 0-7 giorni dopo ogni dose
|
Incidenza di reazioni avverse entro 7 giorni dopo ciascuna dose
|
0-7 giorni dopo ogni dose
|
|
Percentage of participants with pneumococcal serotype-specific IgG antibody concentrations≥0.35 μg/mL .
Lasso di tempo: 30 days after dose 3.
|
Non-inferiority criterion: The lower limit of the two-sided 95% CI for the difference (Sinovac-PCV13 minus Prevenar 13™) > -10% for each serotype at 30 days after dose 3.
|
30 days after dose 3.
|
|
Geometric mean concentrations (GMCs ) of serotype-specific IgG antibody.
Lasso di tempo: 30 days after dose 3.
|
Non-inferiority criterion: The lower limit of the two-sided 95% CI for the GMC ratio (Sinovac-PCV13/Prevenar 13™) > 0.5 for each serotype at 30 days after dose 3.
|
30 days after dose 3.
|
|
Percentage of participants with serotype-specific IgG concentrations ≥ 1.0 μg/mL
Lasso di tempo: 30 days after dose 2
|
Percentage of participants with serotype-specific IgG concentrations ≥ 1.0 μg/mL at 30 days after dose 2
|
30 days after dose 2
|
|
Percentage of participants with serotype-specific IgG concentrations ≥ 1.0 μg/mL .
Lasso di tempo: 30 days after dose 3
|
Percentage of participants with serotype-specific IgG concentrations ≥ 1.0 μg/mL at 30 days after dose 3.
|
30 days after dose 3
|
|
GMC fold increases (GMFRs) in IgG antibody concentrations.
Lasso di tempo: From before dose 3 to 30 days after dose 3
|
GMC fold increases (GMFRs) in IgG antibody concentrations from before dose 3 to 30 days after dose 3.
|
From before dose 3 to 30 days after dose 3
|
|
Percentage of participants with serotype-specific opsonophagocytosis assay (OPA) antibody titers ≥1:8
Lasso di tempo: 30 days after the dose 2.
|
Percentage of participants with serotype-specific OPA antibody titers ≥1:8 at 30 days after the dose 2.
|
30 days after the dose 2.
|
|
Percentage of participants with serotype-specific OPA antibody titers ≥1:8.
Lasso di tempo: 30 days after the dose 3.
|
Percentage of participants with serotype-specific OPA antibody titers ≥1:8 at 30 days after the dose 3.
|
30 days after the dose 3.
|
|
Geometric mean titers (GMTs) of serotype-specific OPA antibody.
Lasso di tempo: 30 days after dose 2.
|
Geometric mean titers (GMTs) of serotype-specific OPA antibody 30 days after dose 2.
|
30 days after dose 2.
|
|
GMTs of serotype-specific OPA antibody .
Lasso di tempo: 30 days after dose 3.
|
GMTs of serotype-specific OPA antibody at 30 days after dose 3.
|
30 days after dose 3.
|
|
GMT fold rises (GMFRs) in OPA titers.
Lasso di tempo: From before dose 3 to 30 days after dose 3.
|
GMT fold rises (GMFRs) in OPA titers from before dose 3 to 30 days after dose 3.
|
From before dose 3 to 30 days after dose 3.
|
|
Incidence of adverse reactions
Lasso di tempo: 0-30 days after each dose.
|
Incidence of adverse reactions within 30 days after each dose.
|
0-30 days after each dose.
|
|
Incidence of serious adverse events(SAEs)
Lasso di tempo: From dose 1 to 30 days after dose 3
|
Incidence of SAEs from dose 1 to 30 days after dose 3
|
From dose 1 to 30 days after dose 3
|
|
Percentage of infants with anti-diphtheria toxoid IgG concentrations ≥ 0.1 IU/mL
Lasso di tempo: 30 days after dose 3 of DTwP-HepB-Hib
|
Percentage of infants with anti-diphtheria toxoid IgG concentrations ≥ 0.1 IU/mL at 30 days after dose 3 of DTwP-HepB-Hib
|
30 days after dose 3 of DTwP-HepB-Hib
|
|
Percentage of infants with anti-tetanus toxoid IgG concentrations ≥ 0.1 IU/mL
Lasso di tempo: 30 days after dose 3 of DTwP-HepB-Hib
|
Percentage of infants with anti-tetanus toxoid IgG concentrations ≥ 0.1 IU/mL at 30 days after dose 3 of DTwP-HepB-Hib
|
30 days after dose 3 of DTwP-HepB-Hib
|
|
Percentage of participants achieving an anti-acellular pertussis (PT, FHA and PRN antigens) antibody concentration
Lasso di tempo: 30 days after dose 3 of DTwP-HepB-Hib
|
Percentage of participants achieving an anti-acellular pertussis (PT, FHA and PRN antigens) antibody concentration ≥ the observed anti-pertussis antibody concentration achieved by 95% of Prevenar 13™ recipients at 30 days after dose 3 of DTwP-HepB-Hib
|
30 days after dose 3 of DTwP-HepB-Hib
|
|
Percentage of infants with anti-Haemophilus influenzae type b (PRP) IgG concentration≥0.15 µg/mL
Lasso di tempo: 30 days after dose 3 of DTwP-HepB-Hib
|
Percentage of infants with anti-Haemophilus influenzae type b (PRP) IgG concentration≥0.15
µg/mL at 30 days after dose 3 of DTwP-HepB-Hib
|
30 days after dose 3 of DTwP-HepB-Hib
|
|
Percentage of infants with anti-Hepatitis B surface antigen (HBsAg) antibody concentrations≥10 mIU/mL
Lasso di tempo: 30 days after dose 3 of DTwP-HepB-Hib
|
Percentage of infants with anti-Hepatitis B surface antigen (HBsAg) antibody concentrations≥10 mIU/mL at 30 days after dose 3 of DTwP-HepB-Hib
|
30 days after dose 3 of DTwP-HepB-Hib
|
|
Percentage of infants with anti-poliovirus types 1, 2 and 3 neutralizing antibody titers≥1:8
Lasso di tempo: 30 days after dose 3 of IPV
|
Percentage of infants with anti-poliovirus types 1, 2 and 3 neutralizing antibody titers≥1:8 measured at 30 days after dose 3 of IPV
|
30 days after dose 3 of IPV
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Edison Alberto, Health Index Multispecialty Clinic (HIMC) Research and Development on Medical Sciences
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- PRO-PCV13-3003
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .